Great West Life Assurance Co. Can raised its stake in shares of Cynosure Inc. (NASDAQ:CYNO) by 3.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 32,014 shares of the company’s stock after buying an additional 1,196 shares during the period. Great West Life Assurance Co. Can owned 0.13% of Cynosure worth $1,630,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the stock. BlackRock Group LTD raised its position in shares of Cynosure by 8.6% in the first quarter. BlackRock Group LTD now owns 23,874 shares of the company’s stock valued at $1,053,000 after buying an additional 1,897 shares during the last quarter. A.R.T. Advisors LLC acquired a new position in shares of Cynosure during the first quarter valued at $1,132,000. Barclays PLC raised its position in shares of Cynosure by 170,900.0% in the first quarter. Barclays PLC now owns 17,100 shares of the company’s stock valued at $752,000 after buying an additional 17,090 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of Cynosure by 120.7% in the second quarter. BNP Paribas Arbitrage SA now owns 7,366 shares of the company’s stock valued at $358,000 after buying an additional 4,028 shares during the last quarter. Finally, Capstone Asset Management Co. raised its position in shares of Cynosure by 17.3% in the second quarter. Capstone Asset Management Co. now owns 10,916 shares of the company’s stock valued at $531,000 after buying an additional 1,610 shares during the last quarter. 99.89% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Cynosure (NASDAQ:CYNO)

Shares of Cynosure Inc. (NASDAQ:CYNO) traded down 1.20% during midday trading on Wednesday, hitting $45.35. 297,486 shares of the stock traded hands. The company has a market capitalization of $1.08 billion, a PE ratio of 51.24 and a beta of 1.71. Cynosure Inc. has a 12-month low of $32.90 and a 12-month high of $55.94. The firm’s 50 day moving average price is $45.39 and its 200 day moving average price is $49.43.

Cynosure (NASDAQ:CYNO) last released its earnings results on Tuesday, October 25th. The company reported $0.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.01. The firm had revenue of $106.40 million for the quarter, compared to analysts’ expectations of $101.11 million. Cynosure had a return on equity of 6.82% and a net margin of 4.97%. The business’s quarterly revenue was up 35.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.21 EPS. Analysts expect that Cynosure Inc. will post $1.28 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Financial Market News and is the propert of of Financial Market News. If you are viewing this piece of content on another website, it was illegally stolen and republished in violation of international trademark and copyright legislation. The legal version of this piece of content can be viewed at http://www.financial-market-news.com/great-west-life-assurance-co-can-acquires-1196-shares-of-cynosure-inc-cyno/1211478/.

CYNO has been the topic of several recent research reports. Brean Capital set a $60.00 price objective on shares of Cynosure and gave the company a “buy” rating in a research report on Wednesday, September 14th. Zacks Investment Research upgraded Cynosure from a “hold” rating to a “buy” rating and set a $59.00 price target on the stock in a report on Tuesday, September 27th. Stifel Nicolaus reiterated a “buy” rating and set a $58.00 price target (down previously from $62.00) on shares of Cynosure in a report on Wednesday, October 26th. Leerink Swann reiterated an “outperform” rating and set a $60.00 price target (down previously from $63.00) on shares of Cynosure in a report on Friday, October 28th. Finally, Aegis started coverage on Cynosure in a report on Wednesday, November 2nd. They set a “buy” rating and a $60.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $60.43.

In other Cynosure news, Chairman Michael R. Davin sold 16,284 shares of the business’s stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $45.00, for a total value of $732,780.00. Following the sale, the chairman now owns 4,222 shares in the company, valued at approximately $189,990. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Douglas J. Delaney sold 7,875 shares of the business’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $45.00, for a total value of $354,375.00. Following the completion of the sale, the vice president now owns 5,833 shares in the company, valued at approximately $262,485. The disclosure for this sale can be found here. 2.90% of the stock is owned by company insiders.

Cynosure Company Profile

Cynosure Inc (Cynosure) develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health.

5 Day Chart for NASDAQ:CYNO

Want to see what other hedge funds are holding CYNO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cynosure Inc. (NASDAQ:CYNO).

Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.